<< Former President Bill Clinton to be the keynote speaker at the Annual Speaker Series Luncheon | Prism Medical to raise funds for strategic acquisitions and to retire debt >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Русский | Svenska | Polski

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Published on August 28, 2009 at 7:54 AM · No Comments

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

"Boston Scientific is proud to be the exclusive sponsor of the landmark MADIT-CRT trial, and we look forward to the presentation of the final data at ESC," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "MADIT-CRT is breaking new ground by demonstrating that early intervention with cardiac resynchronization defibrillation therapy (CRT-D) slows the progression of heart failure when compared to standard implantable cardioverter defibrillator (ICD) therapy. We are also looking forward to the presentation of two-year data from our SYNTAX trial, comparing the use of percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery in patients with complex disease. We are hopeful these results will build on the one-year data, which showed comparable safety outcomes for PCI and CABG."

Details of the Company's activities at ESC are below.

Schedule of Events (All times are local Barcelona; all events are held at the Fira Gran Via Convention Center.)

Sunday, August 30

  • HORIZONS-AMI Trial Results. One-year data from the HORIZONS-AMI trial will be presented in a poster session at 8:30 a.m. The trial was designed to determine the safety and efficacy of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI). Results will focus on the relative impact of ischemic complications and varying definitions of major bleeding on one-year mortality in patients with AMI.

Monday, August 31

  • Clinical Seminar - The SYNTAX Trial: One Year On. The Company will sponsor a clinical seminar chaired by Miguel Sousa Uva, M.D., and Antonio Colombo, M.D., from 4:30-6:00 p.m. in the Madrid Room. Discussion topics will include the view of the non-interventional cardiologist and conclusions from subgroup analyses.

Tuesday, September 1

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading